A

Adverum Biotechnologies

D
ADVM
USD
-0.02
(-0.2525%)
Market Closed
3,481.00
Volume
-4.97
EPS
-
Div Yield
-1.001267
P/E
164,327,133.70
Market Cap
Today
-0.2525%
1 Week
8.293%
1 Month
6.040%
6 Months
-23.375%
12 Months
-14.871%
Year To Date
4.942%
All Time
0%

Title:
Adverum Biotechnologies

Sector:
Healthcare
Industry:
Biotechnology
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Do you need help or have a question?